Figure 3

hENT1 mRNA expression in relation to in vitro ara-C sensitivity. AML patient samples were divided into three groups based on in vitro ara-C sensitivity (sensitive=LC₅₀<0.98 μ M), intermediate=0.98<LC₅₀ <5.18 μ M) and resistant=LC₅₀>5.18 μ M) (Zwaan et al, 2000). Patient resistant to ara-C in vitro expressed 3.0-fold lower hENT1 mRNA levels compared to sensitive patients. The lines indicate the median value. P-value determined by one-way ANOVA.